Brief: Portage Biotech resumes enrollment in final group of its early-stage study for its cancer treatments
12/03/2025 14:15
March 12 (Reuters) - Portage Biotech Inc PRTG.O: PORTAGE BIOTECH RESUMES ENROLLMENT IN FINAL COHORT OF DOSE ESCALATION FOR PORT-6 IN ADPORT-601 TRIAL PORTAGE BIOTECH : ENCOURAGING SAFETY PROFILE SUPPORTS PROGRESSION TOWARD FIRST DUAL-ADMINISTRATION OF SELECTIVE A2A AND A2B ANTAGONISTS IN PATIENTS Further company coverage: PRTG.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alpha Compute
See all newsBrief: Alpha Compute Corp. Provides Mid-Q2 2026 Update
Brief: Alpha Compute Ai Gpu Launch Update First Large-Scale Nvidia Blackwell Cluster
Brief: Alpha Compute Appoints Tom Richer To Advisory Board To Accelerate Ai Gpu Compute Infrastructure And Confidential Cloud Strategy
Brief: Alphaton Capital Rebrands As Alpha Compute Corp. To Reflect Its Growing Ai Compute Business
Brief: Alphaton Capital Announces $43 Million Ai Infrastructure And Financing Partnership With Vertical Data